708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years

Authors :: M. Brausi
J. Oddens
R. Sylvester
S. Colette
P. Gontero
A. Bono
L. Turkeri
Source :: European Urology Supplements. 12:e708
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: Oncology
medicine.medical_specialty
Randomized controlled trial
business.industry
law
Urology
Internal medicine
medicine
Papillary carcinoma
business
law.invention

Full Text Access

Tools